Nasdaq · Healthcare
biote Corp. (BTMD)
As-reported financials and recent SEC filings for biote Corp., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$192.2M
Net income
$27.0M
Net margin
14.1%
Diluted EPS
$0.74
ROE
-53.7%
P/E (TTM)
—
Market cap
—
Debt / equity
-1.9×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $192.2M | $197.2M | $185.4M | $165.0M | $139.4M |
| Gross profit | — | — | — | — | — |
| Operating income | $35.6M | $31.6M | $28.7M | $-60.7M | $34.6M |
| Net income | $27.0M | $3.2M | $3.3M | $-969,000 | $11.1M |
| Diluted EPS | $0.74 | $0.09 | $0.13 | $-0.04 | — |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K/A2026-06-17
View on EDGAR →42026-06-16
View on EDGAR →42026-06-10
View on EDGAR →42026-06-10
View on EDGAR →8-K2026-06-02
View on EDGAR →8-K2026-05-18
View on EDGAR →42026-05-14
View on EDGAR →42026-05-13
View on EDGAR →Largest Healthcare peers
Go deeper on BTMD
Search biote Corp.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.